CME Group stock has given investors a solid 5 year return, yet current checks suggest it is not obviously cheap, with the Excess Returns intrinsic value estimate sitting close to the market price while earnings based multiples point to a premium.

• CME Group has returned about 37% over the past 5 years, which is respectable but not a runaway result that clearly justifies paying any price.
• New product launches such as Treasury Link and expanded agriculture contracts can support long term fee growth expectations, but rising competition in derivatives and alternative trading venues may pressure how much of that growth the company can keep.
• With a value score of 2 out of 6, CME Group currently screens as leaning expensive rather than a clear bargain on the broader valuation checks.

The key question now is whether CME Group's recent share price weakness has reset expectations enough, or if the stock still embeds too much optimism compared with its intrinsic value.

Where Does CME Group Sit on Excess Returns?

The Excess Returns model looks at how much value CME Group creates above the cost of its equity capital. For CME Group, the model uses a Book Value of $73.57 per share and a Stable EPS of $12.95 per share, compared with a Cost of Equity of $6.40 per share and an Excess Return of $6.55 per share. That profile is supported by an Average Return on Equity of 15.92% and a projected Stable Book Value of $81.34 per share. Together, these figures suggest a business expected to keep generating returns above its funding cost rather than relying on aggressive growth assumptions.

On these inputs, Excess Returns arrives at an intrinsic value of $232.54 per share, which sits slightly below the current share price and implies the stock screens about 2.1% overvalued. Because CME Group's recent Q1 results fell short of analyst expectations and the stock dropped after the update, the small premium in the model indicates the market is still paying up for the quality of its return profile despite that setback.

Overall, CME Group appears roughly fairly valued with a mild tilt toward expensive on the Excess Returns view.

CME Group is fairly valued according to our Excess Returns, but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Has CME Group Run Too Far on Earnings?

The P/E ratio suits CME Group because earnings are a key driver of how investors value mature, fee based exchanges. On this metric, CME Group trades at about 20.3x earnings, which is below the Capital Markets industry average of 40.3x and the peer average of 26.9x. That headline discount to the wider group can look tempting if you only compare against raw sector multiples.

The fair P/E ratio implied by the model, however, is 16.4x, which is lower than CME Group’s current 20.3x. In other words, when you adjust for the company’s size, profitability profile and risks, the stock screens as overvalued on earnings rather than cheap. The recent Q1 miss, followed by a share price drop, has not pulled the multiple down to a point where it lines up with this fair P/E estimate.

On the P/E test, CME Group screens as overvalued, with the market paying a richer price for its earnings than the tailored fair multiple suggests.

The CME Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CME Group pick up where the valuation checks leave off by explaining which combinations of future growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than today's price. Instead of stopping at a single output from a ratio or model, they describe the future that number assumes, so you can follow how CME Group's actual progress lines up with that story over time on the Community page.

If you have a number-backed view on whether CME Group's new offerings such as Treasury Link, the Agriculture Index or Sorghum basis futures can support the current valuation, this is a chance to add your voice to the Simply Wall St community with a clear, data-driven narrative. Put your case on CME Group now and see how it stacks up as new contracts, competitor moves and future results shape the story over time.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

The Bottom Line

For CME Group, the Excess Returns intrinsic value estimate and the broader valuation checks both point to a stock that leans toward fully priced rather than clearly cheap. The intrinsic value comes in slightly below the current share price, while the tailored P/E work suggests the stock is overvalued relative to its earnings power. Together with a weak overall value score, that leaves the debate focused on whether CME Group can sustain the quality of its returns and product economics well enough for today’s premium to hold, or whether the multiple eventually settles closer to the fair ratio implied by earnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.